Phase I evaluation of radiation combined with recombinant interferon alpha-2a and BCNU for patients with high-grade glioma

International Journal of Radiation Oncology Biology Physics

Volumn 40, Issue 2, 1998, Pages 297-302

  Rajkumar, S Vincent ^a   Buckner, Jan C ^a   Schomberg, Paula J ^a   Cascino, Terrence L ^a   Burch, Patrick A ^a   Dinapoli, Robert P ^a  

^a MAYO CLINIC   (United States)

Author keywords

Brain tumors; Chemotherapy; Interferons

Indexed keywords

CARMUSTINE; RECOMBINANT ALPHA2A INTERFERON;

ADULT; AGED; ALOPECIA; ANOREXIA; ARTICLE; ASTROCYTOMA; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER RADIOTHERAPY; CANCER SURVIVAL; CENTRAL NERVOUS SYSTEM DEPRESSION; CHILL; CLINICAL ARTICLE; CLINICAL TRIAL; EYE TOXICITY; FEMALE; FEVER; FLU LIKE SYNDROME; GLIOMA; GLIOSARCOMA; HEADACHE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LETHARGY; LUNG TOXICITY; MALE; MYALGIA; NAUSEA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RADIATION NECROSIS; SIDE EFFECT; SUBCUTANEOUS DRUG ADMINISTRATION; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; CARMUSTINE; COMBINED MODALITY THERAPY; FEMALE; GLIOMA; HUMANS; INTERFERON ALFA-2A; MALE; MIDDLE AGED; RADIOTHERAPY; SURVIVAL ANALYSIS;

EID: 0032518351     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0360-3016(97)00739-6     Document Type: Article

References (22)

1. 1. Agarwala, S. S.; Kirkwood, J. M. Interferons in the therapy of solid tumors. Oncology 51:129-36; 1994.
2. 2. Borden, E. C. Interferons. In: Holland, J. F., Frei, E. F. III; Bast, R. C.; Kufe, D. W.; Motion, D. L.; Weichselbaum, R. R., eds. Cancer medicine. Philadelphia, PA: Lea & Febiger; 1993: 927-936.
3. 3. Brandes, A.; Rigon, A.; Zampieri, P.; Scelzi, E.; Zorat, P. L.; Rotilio, A.; Amista, P.; Paccagnella, A.; Fiorentino, M. V. Phase II trial with BCNU plus interferon alfa-2B (IFN) in patients (pts) with recurrent high grade gliomas (Abstr.). Fourth International Congress on Anti-Cancer Chemotherapy. Paris, France; 1993:116.
4. 4. Buckner, J. C.; Brown, L. D.; Kugler, J. W.; Cascino, T. L.; Krook, J. E.; Mailliard, J. A.; Kardinal, C. G.; Tschetter, L. K.; O'Fallon, J. R.; Scheithauer, B. W. Phase II evaluation of recombinant interferon alpha and BCNU in recurrent glioma. J. Neurosurg. 82:430-5; 1995.
5. 5. Canobbio, L.; Miglietta, L.; Boccardo, F. Medical treatment of advanced renal cell carcinoma: present options and future directions. Cancer Treat. Rev. 22:85-104; 1996.
6. 6. Chirigos, M. A.; Pearson, J. W. Brief communication: Cure of murine leukemia with drug and interferon treatment. J. Natl. Cancer Inst. 51:1367-8; 1973.
7. 7. Creagan, E. T.; Kovach, J. S.; Long, H. J.; Richardson, R. L. Phase I study of recombinant leukocyte A human interferon combined with BCNU in selected patients with advanced cancer. J. Clin. Oncol. 4:408-13; 1986.
8. 8. Dillman, R. O.; Wiemann, M.; Oldham, R. K.; Soori, G.; Bury, M.; Hafer, R.; Church C.; DePriest C. Interferon alpha-2a and external beam radiotherapy in the initial management of patients with glioma: a pilot study of the National Biotherapy Study Group. Cancer Biother. 10:265-71; 1995.
9. 9. Fine, H. A. The basis for current treatment recommendations for malignant gliomas. J. Neuro-Oncol. 20:111-20; 1994.
10. 10. Fine, H. A. Novel biologic therapies for malignant gliomas. Antiangiogenesis, immunotherapy, and gene therapy. Neurol. Clin. 13:827-46; 1995.
11. 11. Fine, H. A.; Dear, K. B.; Loeffler, J. S.; Black, P. M.; Canellos, G. P. Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults. Cancer 71:2585-97; 1993.
12. 12. Fine, H. A.; Wen, P.; Alexander, E.; Black, P. M.; Loeffler, J. S. Alpha interferon; BCNU and 5-fluorouracil (5-FU) in the treatment of recurrent high-grade astrocytomas (Abstr.). Proc. Am. Soc. Clin. Oncol. 12:495; 1993.
13. 13. Green, S. B.; Byar, D. P.; Walker, M. D.; Pistenmaa, D. A.; Alexander, E. Jr.; Batzdorf, U.; Brooks, W. H.; Hunt, W. E.; Mealey, J. Jr.; Odom, G. L.; Paoletti, P.; Ransohoff, J. II; Robertson, J. T.; Selker, R. G.; Shapiro, W. R.; Smith, K. R. Jr.; Wilson, C. B.; Strike, T. A. Comparisons of carmustine, procarbazine, and high-dose methylprednisolone as additions to surgery and radiotherapy for the treatment of malignant glioma. Cancer, Treat. Rep. 67:121-32; 1983.
14. 14. Jereb, B.; Petric-Grabnar, G.; Klun, B.; Lamovec, J.; Skrbec, M.; Soos, E. Addition of IFN-alpha to treatment of malignant brain tumors. Acta Oncol. 33:651-4; 1994.
15. 15. Jeremic, B.; Jovanovic, D.; Djuric, L. J.; Jevremovic, S.; Mijatovic, L. J. Advantage of post-radiotherapy chemotherapy with CCNU, procarbazine, and vincristine (mPCV) over chemotherapy with VM-26 and CCNU for malignant gliomas. J. Chemother. 4:123-126; 1992.
16. 16. Kleihues, P.; Burger, P. C.; Scheithauer, B. W. Histological typing of tumours of the central nervous system. World Health Organization, International histological classification of tumours. Berlin, Heidelberg: Springer-Verlag; 1993.
17. 17. Levin, V. A.; Silver, P.; Hannigan, J.; Wara, W. M.; Gutin, P. H.; Davis, R. L.; Wilson, C. B. Superiority of post-radiotherapy adjuvant chemotherapy with CCNU, procarbazine, and vincristine (PCV) over BCNU for anaplastic gliomas: NCOG 6G61 final report. Int. J. Radiat. Oncol. Biol. Phys. 18:321-324; 1990.
18. 18. Nelson, D. F.; Diener-West, M.; Horton, J.; Chang, C. H.; Schoenfeld, D.; Nelson, J. S. Combined modality approach to treatment of malignant gliomas - Re-evaluation of RTOG 7401/ECOG 1374 with long-term follow-up: A joint study of the Radiation Therapy Oncology Group and the Eastern Cooperative Oncology Group. NCI Monogr. 6:279-284; 1988.
19. 19. Priestman, T. J.; Bleehen, N. M.; Rampling, R.; Stenning, S.; Nethersell, A. J.; Scott, J. A phase II evaluation of human lymphoblastoid interferon (Wellferon) in relapsed high grade malignant glioma. Medical Research Council Brain Tumour Working Party. Clin. Oncol. 5:165-8; 1993.
20. 20. Wadler, S.; Schwartz, E. L. Principles in the biomodulation of cytotoxic drugs by interferons. Semin. Oncol. 19(Suppl. 3): 45-8; 1992.
21. 21. Walker, M. D.; Alexander, E. Jr.; Hunt, W. E.; MacCarty, C. S.; Mahaley, M. S. Jr.; Mealey, J. Jr.; Norrell, H. A.; Owens, G.; Ransohoff, J.; Wilson, C. B.; Gehan, E. A.; Strike, T. A. Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. J. Neurosurg. 49:333-343; 1978.
22. 22. Walker, M. D.; Green, S. B.; Byar, D. P.; Alexander, E. Jr.; Batzdorf, U.; Brooks, W. H.; Hunt, W. E.; MacCarty, C. S.; Mahaley, M. S. Jr.; Mealey, J. Jr.; Owens, G.; Ransohoff, J. II; Robertson, J. T.; Shapiro, W. R.; Smith, K. R. Jr.; Wilson, C. B.; Strike, T. A. Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. N. Engl. J. Med. 303:1323-9; 1980.